Literature DB >> 32381539

Gadolinium Deposition Safety: Seeking the Patient's Perspective.

C A Mallio, C C Quattrocchi, À Rovira, P M Parizel.   

Abstract

Entities:  

Year:  2020        PMID： 32381539      PMCID： PMC7342758          DOI： 10.3174/ajnr.A6586

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN： 0195-6108            Impact factor:   3.825


× No keyword cloud information.
  34 in total

1.  Association Between Gadolinium Contrast Exposure and the Risk of Parkinsonism.

Authors:  Blayne Welk; Eric McArthur; Sarah A Morrow; Penny MacDonald; Jade Hayward; Andrew Leung; Andrea Lum
Journal:  JAMA       Date:  2016-07-05       Impact factor: 56.272

Review 2.  Immediate Allergic Reactions to Gadolinium-based Contrast Agents: A Systematic Review and Meta-Analysis.

Authors:  Ashkan Heshmatzadeh Behzadi; Yize Zhao; Zerwa Farooq; Martin R Prince
Journal:  Radiology       Date:  2017-08-25       Impact factor: 11.105

3.  Deep learning enables reduced gadolinium dose for contrast-enhanced brain MRI.

Authors:  Enhao Gong; John M Pauly; Max Wintermark; Greg Zaharchuk
Journal:  J Magn Reson Imaging       Date:  2018-02-13       Impact factor: 4.813

4.  Iron Oxide Nanoparticle Based Contrast Agents for Magnetic Resonance Imaging.

Authors:  Zheyu Shen; Aiguo Wu; Xiaoyuan Chen
Journal:  Mol Pharm       Date:  2016-10-31       Impact factor: 4.939

5.  Gadolinium deposition disease: Initial description of a disease that has been around for a while.

Authors:  Richard C Semelka; Joana Ramalho; Ami Vakharia; Mamdoh AlObaidy; Lauren M Burke; Michael Jay; Miguel Ramalho
Journal:  Magn Reson Imaging       Date:  2016-08-13       Impact factor: 2.546

Review 6.  Gadolinium chelates in angiography and interventional radiology: a useful alternative to iodinated contrast media for angiography.

Authors:  David J Spinosa; John A Kaufmann; Gary D Hartwell
Journal:  Radiology       Date:  2002-05       Impact factor: 11.105

Review 7.  Gadolinium deposition in the brain: summary of evidence and recommendations.

Authors:  Vikas Gulani; Fernando Calamante; Frank G Shellock; Emanuel Kanal; Scott B Reeder
Journal:  Lancet Neurol       Date:  2017-06-13       Impact factor: 44.182

8.  Gadolinium retention after administration of contrast agents based on linear chelators and the recommendations of the European Medicines Agency.

Authors:  Ilona A Dekkers; Rick Roos; Aart J van der Molen
Journal:  Eur Radiol       Date:  2017-10-23       Impact factor: 5.315

9.  Gadolinium-DOTA enhanced MR imaging of intracranial lesions.

Authors:  P M Parizel; H R Degryse; J Gheuens; J J Martin; M Van Vyve; C De La Porte; P Selosse; P Van de Heyning; A M De Schepper
Journal:  J Comput Assist Tomogr       Date:  1989 May-Jun       Impact factor: 1.826

10.  High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material.

Authors:  Tomonori Kanda; Kazunari Ishii; Hiroki Kawaguchi; Kazuhiro Kitajima; Daisuke Takenaka
Journal:  Radiology       Date:  2013-12-07       Impact factor: 11.105
View more
  2 in total

1.  Dentate-nucleus gadolinium deposition on magnetic resonance imaging: ultrasonographic and clinical correlates in multiple sclerosis patients.

Authors:  Isabelle Kühn; Henning Maschke; Annette Großmann; Karlheinz Hauenstein; Marc-André Weber; Uwe K Zettl; Alexander Storch; Uwe Walter
Journal:  Neurol Sci       Date:  2021-11-04       Impact factor: 3.830

2.  Anterior pituitary gland T1 signal intensity is influenced by time delay after injection of gadodiamide.

Authors:  Carlo A Mallio; Laura Messina; Marco Parillo; Gianguido Lo Vullo; Bruno Beomonte Zobel; Paul M Parizel; Carlo C Quattrocchi
Journal:  Sci Rep       Date:  2020-09-11       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.